Adjuvanted Influenza Vaccines
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Adjuvants".
Deadline for manuscript submissions: closed (20 February 2022) | Viewed by 3599
Special Issue Editors
Interests: viral immunology; innate immunity; adaptive immunity; adjuvants; vaccines; immune pathways; fish immunology; rhabdovirus; virus-host interaction; RNA virus; DNA virus
Special Issues, Collections and Topics in MDPI journals
Interests: vaccines; adjuvants; inflammation; formulation; small molecules; antigen presenting cells; macrophages; dendritic cells, Immunology; pharmacology; vascular biology; molecular biology; cellular signaling pathways; kinases; phosphatase; TLR; MAPK; vaccine safety; influenza; SARS-CoV2; tissue culture
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Despite current influenza vaccines being immunogenic, the evolution of the influenza virus can reduce their efficacy, so influenza remains a major threat to public health. One approach to improving influenza vaccines is to include adjuvants. An immunologic adjuvant is defined as a substance that acts to accelerate, prolong, or enhance antigen-specific immune responses when used in combination with specific vaccine antigens. Adjuvants are particularly beneficial for influenza vaccines administered during a pandemic, when a rapid response is required or for use in patients with impaired immune responses. To date, six adjuvants have been used in licensed human vaccines: Alum, MF59, AS03, AF03, virosomes, and heat-labile enterotoxin (LT).
This issue will address the potential of novel adjuvant strategies to modulate innate and adaptive immune responses to facilitate the development of improved prophylactic or therapeutic vaccines. Submission of original articles and systematic reviews is welcome. Manuscripts will follow standard journal peer-review practices, and those accepted for publication will appear in the Special Issue, “Adjuvanted Influenza Vaccines”. We look forward to receiving and welcome your contributions.
Dr. Eduardo Gomez-Casado
Dr. Dheeraj Soni
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- adjuvant
- vaccine
- particulate adjuvant
- innate immunity
- adaptive immunity
- nanoparticle
- AS03
- Alum
- MF59
- antibody
- formulation
